• Secarna GmbH & Co. KG
  • Am Klopferspitz 19
  • 82152 Planegg-Martinsried
  • Germany
  • Phone: +49 (0)89/21546375
  • Fax: +49 (0)6421//98300599
  • moc.anraces@ofni

Jonas Renz, Geschäftsführer / Managing Director
Christian Pangratz, Geschäftsführer / Managing Directo

About Secarna

Secarna Pharmaceuticals is the leading independent European antisense oligonucleotide (ASO) company with a broad pipeline of innovative therapeutic programs in various stages of pre-clinical development and multiple disease indications. Applying its proprietary LNAplus™ platform, the company is generating molecules with significantly improved potency and a comprehensive safety profile against targets that are difficult to regulate or currently not druggable by conventional approaches. Using state-of-the-art bioinformatics (OligofyerTM), Secarna’s antisense molecules are designed and optimized to meet highest specificity and activity criteria. As a result, there is little to no need for lead optimization which significantly speeds up the discovery and development process compared to conventional therapeutic approaches. LNAplus™ is validated by ten commercial partnering transactions, such as with Evotec and Denali Therapeutics, and various successful in-house projects.

What is your motivation?

At Secarna, we are paving the path for a new generation of therapeutics to give patients hope for innovative treatment options, especially in difficult to treat indications. Our proprietary third-generation antisense oligonucleotide (ASO) platform LNAplusTM enables us to discover and develop novel antisense-ased therapies for challenging or currently undruggable targets. Our pipeline contains over 15 programs focusing on targets in therapeutic areas such as immuno- oncology, immunology, ophthalmology, as well as viral-, neurodegenerative-, fibrotic- and cardiometabolic diseases, where antisense- ased approaches can have clear benefits compared to other therapeutic modalities.

“We are glad to be part of the IZB community and benefit from the professional exchange as we grow Secarna through the next stage of development.”

Christian Pangratz, Geschäftsführer / Managing Director

Secarna is a new breed biopharmaceutical company based in Munich, Germany, We have developed a proprietary drug discovery platform, LNAplus™, for the next generation of antisense oligonucleotides.

Together with our partners in academia and industry, we are developing multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and for anti-viral applications. For more information, please visit www.secarna.com.